Firm
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Matthew Grady of Wolf Greenfield says AI presents an opportunity in patent practice for stronger collaboration between in-house and outside counsel
Discussion hosted by Bird & Bird partners also hears that UK courts’ desire to determine FRAND rates could see the jurisdiction penalised in a similar way to China
Sponsored
Sponsored
-
Sponsored by Bird & BirdWilliam Warne of Bird & Bird describes why some recent judgments have the potential to significantly alter the dynamic in UK FRAND cases -
Sponsored by Liu, Shen & AssociatesYanan Deng and Jinlin Chen of Liu Shen & Associates explain why a good patent portfolio for 5G is so valuable in business
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law looks at the changing trend of how courts are determining the similarity of trademarks in South Korea
-
Sponsored by ABE & PartnersTakanori Abe of Abe & Partners looks at a recent judgment which explored how directors are directly liable for the patent infringement of their companies
-
Sponsored by Patrinos & KilimirisMaria Kilimiris of Patrinos & Kilimiris considers how the EUIPO and Greek courts decided on a trademark dispute on the content of pharma goods
-
Sponsored by Adams & AdamsGodfrey Budeli and Jan-Harm Swanepoel of Adams & Adams explain the latest developments in anti-counterfeiting, in the first of a three-part podcast series on IP enforcement of pharma in Africa
